Scancell (LON:SCLP) Shares Down 3.2% - Should You Sell?

Key Points

• Scancell Holdings plc shares fell by 3.2%, trading at GBX 9.69 ($0.13) during mid-day trading with a volume increase of 44% compared to the average session.
• The company reported a market cap of £99.83 million and a price-to-earnings ratio of -462.50, indicating significant financial challenges.
• Insider Martin Diggle purchased 4.4 million shares of Scancell at GBX 10 per share, highlighting confidence from internal stakeholders.

Scancell Holdings plc (LON:SCLP - Get Free Report)'s share price was down 3.2% during mid-day trading on Wednesday . The stock traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). Approximately 1,336,894 shares were traded during trading, an increase of 44% from the average daily volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Price Performance

The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The company has a 50-day moving average price of GBX 10.15 and a 200-day moving average price of GBX 9.63. The company has a market capitalization of £91.12 million, a price-to-earnings ratio of -422.12 and a beta of 0.35.

Insider Activity

In other Scancell news, insider Martin Diggle acquired 4,400,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was acquired at an average cost of GBX 10 per share, for a total transaction of £440,000. Corporate insiders own 15.15% of the company's stock.

About Scancell

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.